Secondaries announced 11.16.2016
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Aclaris Therapeutics, Inc. Symbol: ACRS Price: Last trade $22.86 Trade Date: 11/18 Shares: 2.8 million Underwriter(s)Jefferies, Leerink Partners, Guggenheim Securities CoManager(s)William[…]